Clinical outcome of ultra low-dose decitabine combined with reduced-intensity CAG therapeutic regimen on intermediate or high risk myelodysplastic syndrome

Objective To observe the clinical outcome and safety of ultra low-dose of decitabine (DAC) combined with reducedintensity CAG (aclacinomycin, cytarabine, granulocyte colony stimulating factor) therapeutic regimen on intermediate or high risk myelodysplastic syndrome (MDS). Methods Total of 30 patients treated by ultra low-dose DAC combined with reduced-intensity CAG therapeutic regimen in our center from Apr. 2015 to Oct. 2016 were included in this study, and the clinical outcome, adverse reactions, and survival data were recorded. Results Of all the patients, complete remission (CR) rate was 53% (16 cases), partial remission rate (PR) was 17% (5 cases), hematological improvement (HI) rate was 10% (3 cases), total failure (TF) was 20% (6 cases) and overall response rate (ORR) was 80%. Infection was the main adverse event caused by DAC and occurred in 15 patients (50%), with 2 of them severely infected. The median survival time was 11 months (2-18 months) with 24 survived and 4 died. Conclusion Ultra low-dose DAC combined with reduced-intensity CAG therapeutic regimen is effective and safe on intermediate or high risk MDS with lower rate of severe infection and hematological toxicities.